SB 9200 + tenofovir

SB 9200 + tenofovir is an investigational combination therapy for chronic hepatitis B infection. **SB 9200** is an oral small molecule nucleic acid hybrid (SMNH) prodrug (of SB 9000) that activates host immune responses via the viral sensor proteins retinoic acid-inducible gene 1 (RIG-I) and nucleotide-binding oligomerization domain-containing protein 2 (NOD2), leading to induction of interferon-mediated antiviral defense and direct inhibition of viral polymerase access to pre-genomic RNA[2][3]. **Tenofovir** is a nucleotide analog reverse transcriptase inhibitor (NRTI) approved for hepatitis B that inhibits viral DNA polymerase. The combination is being explored for synergistic antiviral efficacy in chronic hepatitis B, with data supporting both sequential and concomitant approaches in clinical development[1][2][3].

Brand names

Viread

Other names

tenofovir disoproxil fumarate